==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1161 which contains 4 entries.


Entry 1
(1) Primary information
ID1674
ThPP IDTh1161
Therapeutic Peptide/Protein NameAlbiglutide
SequenceHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAK view full sequnce in fasta
Functional ClassificationIb
Molecular Weight72970
Chemical FormulaC3232H5032N864O979S41
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half Life4-7 days.
DescriptionAlbiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Indication/DiseaseIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
PharmacodynamicsIt lowers fasting glucose and reduces postprandial glucose excursions in patients with type 2 diabetes mellitus. The majority of the observed reduction in fasting plasma glucose occurs after a single dose, consistent with the pharmacokinetic profile of albiglutide.
Mechanism of ActionAlbiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.
ToxicityRISK OF THYROID C-CELL TUMORS -Albiglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with Albiglutide.O675
MetabolismBiotransformation studies have not been performed. Because albiglutide is an albumin fusion protein, it likely follows a metabolic pathway similar to native human serum albumin, which is catabolized primarily in the vascular endothelium.
AbsorptionMaximum concentrations of albiglutide were reached at 3 to 5 days post-dosing following a single 30mg dose. The mean peak concentration (Cmax) and mean area under the time-concentration curve (AUC) of albiglutide were 1.74 mcg/mL and 465 mcg.h/mL, respectively.
Volume of Distribution11 L
Clearance67 mL/h
CategoriesDrugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins.
Patents Number
Date of Issue
Date of Expiry
Drug InteractionAcetylsalicylic acid may increase the hypoglycemic activities of Albiglutide; Albiglutide may increase the hypoglycemic activities of Chlorpropamide; Dihydrotestosterone may increase the hypoglycemic activities of Albiglutide; Albiglutide may increase the hypoglycemic activities of Insulin Regular; Albiglutide may increase the hypoglycemic activities of Insulin Lispro; The therapeutic efficacy of Albiglutide can be decreased when used in combination with Leuprolide; Lipoic Acid may increase the hypoglycemic activities of Albiglutide; Oxandrolone may increase the hypoglycemic activities of Albiglutide; Paroxetine may increase the hypoglycemic activities of Albiglutide; Pegvisomant may increase the hypoglycemic activities of Albiglutide.
TargetGlucagon-like peptide 1 receptor
Information of corresponding available drug in the market
Brand NameEperzan
CompanyGlaxosmithkline Inc
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
Formulation50 mg
Physcial Appearancepowder for solution
Route of AdministrationSubcutaneous
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful LinkNA
PubMed ID20383346, 25477585, 25083125, 19455266, 24421551, 19455266
3-D StructureTh1161 (View) or (Download)


Entry 2
(2) Primary information
ID1675
ThPP IDTh1161
Therapeutic Peptide/Protein NameAlbiglutide
SequenceHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAK view full sequnce in fasta
Functional ClassificationIb
Molecular Weight72971
Chemical FormulaC3232H5032N864O979S42
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half Life4-7 days.
DescriptionAlbiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Indication/DiseaseIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
PharmacodynamicsIt lowers fasting glucose and reduces postprandial glucose excursions in patients with type 2 diabetes mellitus. The majority of the observed reduction in fasting plasma glucose occurs after a single dose, consistent with the pharmacokinetic profile of albiglutide.
Mechanism of ActionAlbiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.
ToxicityRISK OF THYROID C-CELL TUMORS -Albiglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with Albiglutide.O675
MetabolismBiotransformation studies have not been performed. Because albiglutide is an albumin fusion protein, it likely follows a metabolic pathway similar to native human serum albumin, which is catabolized primarily in the vascular endothelium.
AbsorptionMaximum concentrations of albiglutide were reached at 3 to 5 days post-dosing following a single 30mg dose. The mean peak concentration (Cmax) and mean area under the time-concentration curve (AUC) of albiglutide were 1.74 mcg/mL and 465 mcg.h/mL, respectively.
Volume of Distribution12 L
Clearance68 mL/h
CategoriesDrugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins.
Patents Number
Date of Issue
Date of Expiry
Drug InteractionAcetylsalicylic acid may increase the hypoglycemic activities of Albiglutide; Albiglutide may increase the hypoglycemic activities of Chlorpropamide; Dihydrotestosterone may increase the hypoglycemic activities of Albiglutide; Albiglutide may increase the hypoglycemic activities of Insulin Regular; Albiglutide may increase the hypoglycemic activities of Insulin Lispro; The therapeutic efficacy of Albiglutide can be decreased when used in combination with Leuprolide; Lipoic Acid may increase the hypoglycemic activities of Albiglutide; Oxandrolone may increase the hypoglycemic activities of Albiglutide; Paroxetine may increase the hypoglycemic activities of Albiglutide; Pegvisomant may increase the hypoglycemic activities of Albiglutide.
TargetGlucagon-like peptide 1 receptor
Information of corresponding available drug in the market
Brand NameEperzan
CompanyGlaxosmithkline Inc
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
Formulation30 mg
Physcial Appearancepowder for solution
Route of AdministrationSubcutaneous
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful LinkNA
PubMed ID20383346, 25477585, 25083125, 19455266, 24421551, 19455266
3-D StructureTh1161 (View) or (Download)


Entry 3
(3) Primary information
ID1676
ThPP IDTh1161
Therapeutic Peptide/Protein NameAlbiglutide
SequenceHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAK view full sequnce in fasta
Functional ClassificationIb
Molecular Weight72972
Chemical FormulaC3232H5032N864O979S43
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half Life4-7 days.
DescriptionAlbiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Indication/DiseaseIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
PharmacodynamicsIt lowers fasting glucose and reduces postprandial glucose excursions in patients with type 2 diabetes mellitus. The majority of the observed reduction in fasting plasma glucose occurs after a single dose, consistent with the pharmacokinetic profile of albiglutide.
Mechanism of ActionAlbiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.
ToxicityRISK OF THYROID C-CELL TUMORS -Albiglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with Albiglutide.O675
MetabolismBiotransformation studies have not been performed. Because albiglutide is an albumin fusion protein, it likely follows a metabolic pathway similar to native human serum albumin, which is catabolized primarily in the vascular endothelium.
AbsorptionMaximum concentrations of albiglutide were reached at 3 to 5 days post-dosing following a single 30mg dose. The mean peak concentration (Cmax) and mean area under the time-concentration curve (AUC) of albiglutide were 1.74 mcg/mL and 465 mcg.h/mL, respectively.
Volume of Distribution13 L
Clearance69 mL/h
CategoriesDrugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins.
Patents Number
Date of Issue
Date of Expiry
Drug InteractionAcetylsalicylic acid may increase the hypoglycemic activities of Albiglutide; Albiglutide may increase the hypoglycemic activities of Chlorpropamide; Dihydrotestosterone may increase the hypoglycemic activities of Albiglutide; Albiglutide may increase the hypoglycemic activities of Insulin Regular; Albiglutide may increase the hypoglycemic activities of Insulin Lispro; The therapeutic efficacy of Albiglutide can be decreased when used in combination with Leuprolide; Lipoic Acid may increase the hypoglycemic activities of Albiglutide; Oxandrolone may increase the hypoglycemic activities of Albiglutide; Paroxetine may increase the hypoglycemic activities of Albiglutide; Pegvisomant may increase the hypoglycemic activities of Albiglutide.
TargetGlucagon-like peptide 1 receptor
Information of corresponding available drug in the market
Brand NameTanzeum
CompanyGlaxo Smith Kline Llc
Brand DiscriptionN.A.
Prescribed forA GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Chemical NameN.A.
Formulation30 mg/.5mL
Physcial Appearanceinjection, powder, lyophilized, for solution
Route of AdministrationSubcutaneous
Recommended DosageThe recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. The dosage may be increased to 50 mg once weekly if the glycemic response is inadequate.
ContraindicationContraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); in patients with a prior serious hypersensitivity reaction to albiglutide or to any of the product components
Side EffectsRisk of Thyroid C-cell Tumors; Acute Pancreatitis; Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin ; Hypersensitivity Reactions; Renal Impairment.
Useful Linkhttp://www.rxlist.com/tanzeum-drug/clinical-pharmacology.htm ; https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf
PubMed ID20383346, 25477585, 25083125, 19455266, 24421551, 19455266
3-D StructureTh1161 (View) or (Download)


Entry 4
(4) Primary information
ID1677
ThPP IDTh1161
Therapeutic Peptide/Protein NameAlbiglutide
SequenceHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAK view full sequnce in fasta
Functional ClassificationIb
Molecular Weight72973
Chemical FormulaC3232H5032N864O979S44
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half Life4-7 days.
DescriptionAlbiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Indication/DiseaseIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
PharmacodynamicsIt lowers fasting glucose and reduces postprandial glucose excursions in patients with type 2 diabetes mellitus. The majority of the observed reduction in fasting plasma glucose occurs after a single dose, consistent with the pharmacokinetic profile of albiglutide.
Mechanism of ActionAlbiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.
ToxicityRISK OF THYROID C-CELL TUMORS -Albiglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with Albiglutide.O675
MetabolismBiotransformation studies have not been performed. Because albiglutide is an albumin fusion protein, it likely follows a metabolic pathway similar to native human serum albumin, which is catabolized primarily in the vascular endothelium.
AbsorptionMaximum concentrations of albiglutide were reached at 3 to 5 days post-dosing following a single 30mg dose. The mean peak concentration (Cmax) and mean area under the time-concentration curve (AUC) of albiglutide were 1.74 mcg/mL and 465 mcg.h/mL, respectively.
Volume of Distribution14 L
Clearance70 mL/h
CategoriesDrugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins.
Patents Number
Date of Issue
Date of Expiry
Drug InteractionAcetylsalicylic acid may increase the hypoglycemic activities of Albiglutide; Albiglutide may increase the hypoglycemic activities of Chlorpropamide; Dihydrotestosterone may increase the hypoglycemic activities of Albiglutide; Albiglutide may increase the hypoglycemic activities of Insulin Regular; Albiglutide may increase the hypoglycemic activities of Insulin Lispro; The therapeutic efficacy of Albiglutide can be decreased when used in combination with Leuprolide; Lipoic Acid may increase the hypoglycemic activities of Albiglutide; Oxandrolone may increase the hypoglycemic activities of Albiglutide; Paroxetine may increase the hypoglycemic activities of Albiglutide; Pegvisomant may increase the hypoglycemic activities of Albiglutide.
TargetGlucagon-like peptide 1 receptor
Information of corresponding available drug in the market
Brand NameTanzeum
CompanyGlaxo Smith Kline Llc
Brand DiscriptionN.A.
Prescribed forA GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Chemical NameN.A.
Formulation50 mg/.5mL
Physcial Appearanceinjection, powder, lyophilized, for solution
Route of AdministrationSubcutaneous
Recommended DosageThe recommended dosage of TANZEUM is 30 mg once weekly given as a subcutaneous injection in the abdomen, thigh, or upper arm region. The dosage may be increased to 50 mg once weekly if the glycemic response is inadequate.
ContraindicationContraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); in patients with a prior serious hypersensitivity reaction to albiglutide or to any of the product components
Side EffectsRisk of Thyroid C-cell Tumors; Acute Pancreatitis; Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin ; Hypersensitivity Reactions; Renal Impairment.
Useful Linkhttp://www.rxlist.com/tanzeum-drug/clinical-pharmacology.htm ; https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf
PubMed ID20383346, 25477585, 25083125, 19455266, 24421551, 19455266
3-D StructureTh1161 (View) or (Download)